Biostax Corp (BTAX)

[resx18]

WINTER PARK, Fla., July 20, 2020 /PRNewswire/ — Cytocom, Inc., a private clinical-stage biopharmaceutical company developing novel immune modulating therapies targeting cancer, autoimmune, inflammatory, and infectious diseases based on proprietary platforms, today announced the acquisition of ImQuest Life Sciences, Inc., a research and development company focused specifically on cancer, inflammation and infectious disease treatments, including its subsidiaries in an all-stock transaction.

Subsequent to the acquisition closing, ImQuest Pharmaceuticals, the drug development arm of ImQuest Life Sciences, will be merged into Cytocom’s existing drug development operations. Meanwhile, ImQuest BioSciences, a contract research organization (CRO), will continue to operate as a separate wholly-owned, revenue-generating subsidiary of Cytocom. Financial details of the acquisition were not disclosed.

Founded in 2004, ImQuest Life Sciences provides services and tools to drug makers through its ImQuest BioSciences subsidiary to evaluate vaccines, biologics and pharmaceuticals in preclinical development against infectious diseases, cancer and inflammatory diseases. The company also has a drug development pipeline, built through strategic alliances and exclusive licensing deals, focused on treatments for cancer, HIV, hepatitis B and C, influenza, and drug-resistant microorganisms.